Dr. Jie Jin: the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)
The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023
From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology Department at Shanxi Baiqiu'en Hospital, China, had three research results selected for presentation. Oncology Frontier specially invited Dr. Wei to present the findings.
Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes
Dr. Komrokji delved into the revised classifications for Myelodysplastic Syndromes (MDS) unveiled at the International Congress. The discussion contrasted the 2016 and 2022 editions, spotlighting new molecularly defined subcategories, such as SF3B1 MDS and biallelic p53, alongside morphological distinctions like MDS with increased blast types, hypoplastic MDS, and MDS with fibrosis. Dr. Komrokji's insights underscored the evolving MDS classification landscape and promising therapeutic frontiers, marking a pivotal advancement in understanding MDS and refining patient care.
Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia
Abstract: Dr. Nigel Russell provides insights into the recent developments in the treatment landscape of Acute Myeloid Leukemia (AML). The discussion encompasses the combination of FLT3 mutation inhibitors with intensive chemotherapy, emphasizing the effectiveness and safety demonstrated by the combination of midostaurin with gemtuzumab ozogamicin. The presentation explores emerging FLT3 inhibitors like quizartinib and their potential in combination with chemotherapy. Additionally, Dr. Russell delves into a groundbreaking study involving the combination of the FLAG-Ida regimen with gemtuzumab ozogamicin for patients with NPM1-mutated AML. The study reveals significantly improved event-free and overall survival, indicating a promising therapeutic approach for this patient subgroup. Furthermore, the discussion touches upon the advancements in bispecific antibodies in AML, particularly focusing on blinatumomab's role in targeting CD19 for patients with relapsed core-binding factor leukemia. The potential use of bispecific antibodies in eradicating minimal residual disease after intensive therapy is highlighted, offering a glimpse into a targeted therapeutic strategy for AML patients. Overall, these insights contribute to the evolving landscape of AML treatment, showcasing promising avenues for improving patient outcomes.